PE20011183A1 - Metabolitos agonistas/antagonistas de estrogeno - Google Patents
Metabolitos agonistas/antagonistas de estrogenoInfo
- Publication number
- PE20011183A1 PE20011183A1 PE2001000320A PE2001000320A PE20011183A1 PE 20011183 A1 PE20011183 A1 PE 20011183A1 PE 2001000320 A PE2001000320 A PE 2001000320A PE 2001000320 A PE2001000320 A PE 2001000320A PE 20011183 A1 PE20011183 A1 PE 20011183A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- pyrrolidin
- tetrahidronaftalen
- iletoxy
- metabolites
- Prior art date
Links
- 239000002207 metabolite Substances 0.000 title abstract 3
- 229940011871 estrogen Drugs 0.000 title abstract 2
- 239000000262 estrogen Substances 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
Abstract
SE REFIERE A UN METABOLITO DE (-)-CIS-6-FENIL-5-[4-(2-PIRROLIDIN-1-ILETOXI)FENIL]-5,6,7,8-TETRAHIDRONAFTALEN-2-OL DE FORMULA I DONDE R1 ES EL GRUPO a, b, c, NCH(CH2)3COR6; R5 ES H, CH3; R2, R3, R4 Y R7 SON H, OR5; R6 ES OH, NHCH2COOH SIEMPRE QUE R1 ES AL GRUPO a O -NH(CH2)3COOH; R2 ES OH, OCH3; R3 Y R7 SON H; R2 Y R7 SON H Y R3 ES OH, OCH3, ENTONCES R4 NO ES H. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. SON COMPUESTOS PREFERIDOS 6-FENIL-5-[4-(2-PIRROLIDIN-1-ILETOXI)FENIL]-5,6,7,8-TETRAHIDRONAFTALEN-2,3-DIOL, 3-METOXI-7-FENIL-8-[4-(2-PIRROLIDIN-1-ILETOXI)FENIL]-5,6,7,8-TETRAHIDRONAFTALEN-2-OL,3-METOXI-6-FENIL-5-[4-(2-PIRROLIDIN-1-ILETOXI)FENIL]-5,6,7,8-TETRAHIDRONAFTALEN-2-OL, ENTRE OTROS. LOS METABOLITOS DE FORMULA I REDUCEN LOS EFECTOS ADVERSOS ASOCIADOS A LA ADMINISTRACION DE ESTROGENOS ASIMISMO PUEDEN UTILIZARSE COMO PATRONES EN ENSAYOS ANALITICOS, INTERMEDIOS PARA LA SINTESIS QUIMICA O BIOSINTESIS Y AGENTES TERAPEUTICOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26719800P | 2000-04-07 | 2000-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20011183A1 true PE20011183A1 (es) | 2001-11-14 |
Family
ID=23017734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000320A PE20011183A1 (es) | 2000-04-07 | 2001-04-05 | Metabolitos agonistas/antagonistas de estrogeno |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US6455572B1 (es) |
| EP (1) | EP1268453B1 (es) |
| JP (1) | JP2004510693A (es) |
| KR (1) | KR20020089434A (es) |
| CN (1) | CN1209353C (es) |
| AP (1) | AP2002002641A0 (es) |
| AR (1) | AR035330A1 (es) |
| AT (1) | ATE333450T1 (es) |
| AU (2) | AU2001240985B2 (es) |
| BG (1) | BG107137A (es) |
| BR (1) | BR0109838A (es) |
| CA (1) | CA2405070A1 (es) |
| CR (1) | CR6766A (es) |
| CZ (1) | CZ20023223A3 (es) |
| DE (1) | DE60121557T2 (es) |
| DK (1) | DK1268453T3 (es) |
| EA (1) | EA004866B1 (es) |
| EE (1) | EE200200580A (es) |
| ES (1) | ES2266169T3 (es) |
| HK (1) | HK1052511B (es) |
| HR (1) | HRP20020802A2 (es) |
| HU (1) | HUP0300419A3 (es) |
| IL (1) | IL152082A0 (es) |
| IS (1) | IS6549A (es) |
| MA (1) | MA26890A1 (es) |
| MX (1) | MXPA02009940A (es) |
| NO (1) | NO20024767L (es) |
| OA (1) | OA12325A (es) |
| PA (1) | PA8514901A1 (es) |
| PE (1) | PE20011183A1 (es) |
| PL (1) | PL358593A1 (es) |
| PT (1) | PT1268453E (es) |
| SK (1) | SK14092002A3 (es) |
| TN (1) | TNSN01052A1 (es) |
| TR (1) | TR200202310T2 (es) |
| UY (1) | UY26656A1 (es) |
| WO (1) | WO2001077093A1 (es) |
| ZA (1) | ZA200207995B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US7001926B2 (en) | 2000-03-10 | 2006-02-21 | Oxigene, Inc. | Tubulin binding agents and corresponding prodrug constructs |
| US7091240B2 (en) | 2000-03-10 | 2006-08-15 | Oxigene, Inc. | Tubulin binding ligands and corresponding prodrug constructs |
| CZ20002567A3 (cs) * | 2000-07-11 | 2001-12-12 | Léčiva, A.S. | Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby |
| EP1192945A3 (en) * | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
| AU781168B2 (en) * | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
| WO2003062252A1 (en) * | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Edg receptor agonists |
| WO2003076930A1 (en) * | 2002-03-14 | 2003-09-18 | Warner-Lambert Company Llc | Method for characterizing metabolites using hydrogen/deuterium exchange |
| EP1658036A2 (en) * | 2003-08-26 | 2006-05-24 | Board of Regents of the University of Texas System | Estrogen receptor modulators and uses thereof |
| US7456214B2 (en) | 2004-05-03 | 2008-11-25 | Baylor University | Chromene-containing compounds with anti-tubulin and vascular targeting activity |
| PT1778710E (pt) * | 2004-08-13 | 2012-04-12 | Wyeth Llc | Derivados de tanaproget, metabolitos e suas utilizações |
| AU2012200714B2 (en) * | 2004-08-13 | 2014-04-17 | Wyeth Llc | Tanaproget derivatives, metabolites, and uses thereof |
| DE602006017217D1 (de) * | 2005-06-22 | 2010-11-11 | Pfizer Prod Inc | Stereoselektives hydrierverfahren zur herstellung von cis-6-phenyl-5-ä4-(2-pyrrolidin-1-yl-ethoxy)-phenylü-2-methoxy-5,6,7,8-tetrahydronaphthalin-hydrochlorid |
| US7902147B2 (en) | 2007-11-05 | 2011-03-08 | Duke University | Chronic lymphocytic leukemia prognosis and treatment |
| TW201043595A (en) * | 2009-03-13 | 2010-12-16 | Organon Nv | Tetrahydronaphthalen-2-ol derivatives |
| CN107406424B (zh) * | 2014-12-18 | 2020-08-25 | 豪夫迈·罗氏有限公司 | 雌激素受体调节剂及其用途 |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3522319A (en) * | 1964-01-23 | 1970-07-28 | Ciba Geigy Corp | Phenol substituted tetrahydronaphthalenes useful as estrogenics |
| US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| UA51676C2 (uk) | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
| IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| TW442286B (en) | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
| US6358951B1 (en) * | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
-
2001
- 2001-03-19 PT PT01912069T patent/PT1268453E/pt unknown
- 2001-03-19 AT AT01912069T patent/ATE333450T1/de not_active IP Right Cessation
- 2001-03-19 HR HR20020802A patent/HRP20020802A2/hr not_active Application Discontinuation
- 2001-03-19 KR KR1020027013379A patent/KR20020089434A/ko not_active Ceased
- 2001-03-19 HK HK03104866.0A patent/HK1052511B/zh not_active IP Right Cessation
- 2001-03-19 WO PCT/IB2001/000427 patent/WO2001077093A1/en not_active Ceased
- 2001-03-19 AU AU2001240985A patent/AU2001240985B2/en not_active Ceased
- 2001-03-19 TR TR2002/02310T patent/TR200202310T2/xx unknown
- 2001-03-19 DK DK01912069T patent/DK1268453T3/da active
- 2001-03-19 CZ CZ20023223A patent/CZ20023223A3/cs unknown
- 2001-03-19 DE DE60121557T patent/DE60121557T2/de not_active Expired - Fee Related
- 2001-03-19 MX MXPA02009940A patent/MXPA02009940A/es active IP Right Grant
- 2001-03-19 EE EEP200200580A patent/EE200200580A/xx unknown
- 2001-03-19 SK SK1409-2002A patent/SK14092002A3/sk unknown
- 2001-03-19 PL PL01358593A patent/PL358593A1/xx not_active Application Discontinuation
- 2001-03-19 ES ES01912069T patent/ES2266169T3/es not_active Expired - Lifetime
- 2001-03-19 EA EA200200949A patent/EA004866B1/ru not_active IP Right Cessation
- 2001-03-19 OA OA1200200305A patent/OA12325A/en unknown
- 2001-03-19 JP JP2001575567A patent/JP2004510693A/ja not_active Withdrawn
- 2001-03-19 CN CNB018077935A patent/CN1209353C/zh not_active Expired - Fee Related
- 2001-03-19 AU AU4098501A patent/AU4098501A/xx active Pending
- 2001-03-19 EP EP01912069A patent/EP1268453B1/en not_active Expired - Lifetime
- 2001-03-19 CA CA002405070A patent/CA2405070A1/en not_active Abandoned
- 2001-03-19 HU HU0300419A patent/HUP0300419A3/hu unknown
- 2001-03-19 AP APAP/P/2002/002641A patent/AP2002002641A0/en unknown
- 2001-03-19 IL IL15208201A patent/IL152082A0/xx unknown
- 2001-03-19 BR BR0109838-1A patent/BR0109838A/pt not_active IP Right Cessation
- 2001-04-04 US US09/825,980 patent/US6455572B1/en not_active Ceased
- 2001-04-05 AR ARP010101626A patent/AR035330A1/es unknown
- 2001-04-05 UY UY26656A patent/UY26656A1/es not_active Application Discontinuation
- 2001-04-05 PE PE2001000320A patent/PE20011183A1/es not_active Application Discontinuation
- 2001-04-06 TN TNTNSN01052A patent/TNSN01052A1/fr unknown
- 2001-04-09 PA PA20018514901A patent/PA8514901A1/es unknown
-
2002
- 2002-09-17 IS IS6549A patent/IS6549A/is unknown
- 2002-09-23 BG BG107137A patent/BG107137A/bg unknown
- 2002-10-02 MA MA26847A patent/MA26890A1/fr unknown
- 2002-10-02 CR CR6766A patent/CR6766A/es not_active Application Discontinuation
- 2002-10-03 NO NO20024767A patent/NO20024767L/no not_active Application Discontinuation
- 2002-10-04 ZA ZA200207995A patent/ZA200207995B/en unknown
-
2003
- 2003-05-30 US US10/448,751 patent/USRE39419E1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20011183A1 (es) | Metabolitos agonistas/antagonistas de estrogeno | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| PE20040655A1 (es) | Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienen | |
| PE20011119A1 (es) | Composiciones farmaceuticas de agonista/antagonista de estrogenos para el tratamiento de afecciones que responden a un aumento de testosterona | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| AR064258A1 (es) | Inhibidores macrociclicos del virus de hepatitis c | |
| EA200201179A1 (ru) | Производные 2-аминокарбонил-9h-пурина | |
| NO20053460L (no) | Nye forbindelser med selektiv inhibiterende effekt ved GSK3 | |
| KR910006218A (ko) | 2-아미도테트라린 치환유도체와 이 치환유도체를 포함하는 제약학적 조성물 및 이를 사용한 치료방법 | |
| BR0112856A (pt) | Método para o tratamento dos distúrbios, composto ou um sal ou solvato deste, processo para a preparação dos mesmos, composição farmacêutico, método de tratamento e/ou profilaxia de um ou mais dos distúrbios, uso de um composto, e, método para o tratamento de diabetes, grande depressão, depressão manìaca, ansiedade, esquizofrenia e distúrbios do sono, em mamìferos humanos e não humanos | |
| NO20065112L (no) | Kinolinon-karboksamidforbindelser som 5-HT4 receptoragonister | |
| AR040333A1 (es) | Uso de derivados de ciclotiocarbamatos en el tratamiento de condiciones relacionadas con hormonas | |
| ES2065324T3 (es) | N-(piridinil)-1h-indol-1-aminas, un procedimiento para su preparacion y su uso como medicamentos. | |
| AR031867A1 (es) | Compuestos derivados de fenoxibencilamina como ssri, su uso en la preparacion de medicamentos, procedimiento de preparacion del compuesto e intermediarios utiles | |
| PE20011134A1 (es) | 4-fluoralquil-2h-benzopiranos con efecto antiestrogenico, metodo para su obtencion, preparados farmaceuticos que los contienen y su utilizacion para obtener medicamentos | |
| CO4950553A1 (es) | Compuestos de 7-tetrahidroisoquinolinas y procedimiento para su preparacion | |
| EA200700367A1 (ru) | Новые производные 4-бензилиденпиперидина | |
| AR007079A1 (es) | Derivados de alquilaminobenzotiazol y benzoxazol , un proceso para su preparación, una composición farmacéutica que los contiene, y un proceso para preparar dicha composición | |
| AR067454A1 (es) | Derivados de indano- amina, su preparacion y uso como medicamentos | |
| AR036176A1 (es) | Un derivado de fenil-acetamido-tiazol, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un producto o kit que los comprende, y un metodo que utiliza dicho derivado | |
| AR045939A1 (es) | Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos | |
| PE20021018A1 (es) | DERIVADOS DE ß - CARBOLINA | |
| UY28688A1 (es) | Derivados de amida | |
| AR049650A1 (es) | Derivados 5-aril-1h-pirrol[2,3-b]piridin-3-carboxamida o acido 5-aril-1h-pirrol[2,3-b]piridin-3-carboxilico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |